Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While GHRP-2 is used in research to induce robust GH pulses and study anabolic and metabolic effects; clinically developed as pralmorelin for GH deficiency diagnostics6272, TB-500 is studied for enhancing musculoskeletal and cardiac repair, wound healing, and promoting cell migration and differentiation via actin cytoskeleton remodeling21255.
While GHRP-2 works as a second-generation hexapeptide growth hormone–releasing peptide that mimics ghrelin by agonizing GHSR-1a, strongly stimulating pulsatile GH release and modestly raising prolactin, ACTH, and cortisol62723096, TB-500 is a synthetic peptide comprising the LKKTETQ actin-binding motif of thymosin beta-4 that binds G-actin, sequesters actin monomers, and promotes cell migration, angiogenesis, and tissue repair1255.
GHRP-2
GHSR
TB-500
TMSB4X
GHRP-2 and TB-500 are noticeably different, with limited direct overlap in their usual biological context. Both are often discussed in Musculoskeletal health contexts, while GHRP-2 is more of a hormone peptide and TB-500 is better described as a signal peptide. Their biological logic is quite different: GHRP-2 is a receptor agonist, whereas TB-500 is a signaling modulator and a growth factor mimetic. GHRP-2 has a more synthetic design origin, while TB-500 is closer to synthetic analog background with GHRP-2 in Clinical phase 1 and TB-500 in Preclinical development. GHRP-2 incorporates d-amino acid substitution and amidation features that are not part of TB-500.